According to unpublished research carried out at the Santa Casa de Sao Paulo School of Medical Sciences and published in the journal Neurourology and Urodynamics, women with overactive bladder refractory to first and second line treatments obtained improvement in symptoms and quality of life for a longer period when receiving 500 Intravesical treatment units with ABO (abobotulinumtoxinA) in relation to those receiving 300 units.
In a randomized trial, Danielle de Sá Dantas Bezerra, author of the master’s thesis that resulted in the article, signed by five more researchers, 21 women received 300 or 500 U of ABO.
In the overall impression of patient improvement (IGP-I) questionnaire, 70% of patients in the 300 U group and 88.9% in the 500 U group reported feeling better or better in 12 weeks. At 24 weeks, the percentages were 50% and 100%, respectively.
Team that signs the article: Danielle de Sá Dantas Bezerra, Luis Gustavo Morato de Toledo, Silvia da Silva Carramão, Antonio F. Silva Rodrigues, Roger Dmochowski and Antonio P. F. Auge. Published 12/7/2018. Access: https://doi.org/10.1002/nau.23884